by Virtus | Nov 1, 2026 | Respiratory Preclinical Research
Chronic obstructive pulmonary disease (COPD) is a complex respiratory condition characterised by persistent airflow limitation and a range of pathological changes affecting the lungs. These may include chronic airway inflammation, small airway remodelling and...
by Virtus | Nov 1, 2026 | Respiratory Preclinical Research
Bronchoalveolar lavage (BAL) is an established sampling technique used in respiratory research to investigate the cellular and biochemical environment of the lungs. By collecting fluid from the lower respiratory tract, researchers can examine inflammatory cells,...
by Virtus | Nov 1, 2026 | Respiratory Preclinical Research
In vitro respiratory disease models play an important role in preclinical drug discovery by allowing researchers to investigate lung and airway biology under controlled experimental conditions. These models can help scientists explore disease mechanisms, evaluate...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Preclinical respiratory efficacy studies are an important part of developing new treatments for diseases affecting the lungs and airways. Before a candidate progresses towards clinical development, researchers need evidence that it produces a relevant biological or...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Airway hyperresponsiveness is a key feature of asthma and an important endpoint in preclinical respiratory drug development. It describes an exaggerated narrowing of the airways in response to stimuli that produce a smaller response in healthy airways. Measuring this...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Developing a new respiratory therapeutic requires a clear understanding of disease biology, drug activity and the evidence needed to progress a candidate through preclinical development. For pharmaceutical and biotechnology companies, accessing the right preclinical...